Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?

Richard K Burt*, Shimon Slavin, William H. Burns, Alberto M. Marmont

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations

Abstract

Hematopoietic stem cells (HSCs) are the earliest cells of the immune system, giving rise to B and T lymphocytes, monocytes, tissue macrophages, and dendritic cells. In animal models, adoptive transfer of HSCs, depending on circumstances, may cause, prevent, or cure autoimmune diseases. Clinical trials have reported early remission of otherwise refractory autoimmune disorders after either autologous or allogeneic hematopoietic stem cell transplantation (HSCT). By percentage of transplantations performed, autoimmune diseases are the most rapidly expanding indication for stem cell transplantation. Although numerous editorials or commentaries have been previously published, no prior review has focused on the immunology of transplantation tolerance or development of phase 3 autoimmune HSCT trials. Results from current trials suggest that mobilization of HSCs, conditioning regimen, eligibility and exclusion criteria, toxicity, outcome, source of stem cells, and posttransplantation follow-up need to be disease specific. HSCT-induced remission of an autoimmune disease allows for a prospective analysis of events involved in immune tolerance not available in cross-sectional studies.

Original languageEnglish (US)
Pages (from-to)226-247
Number of pages22
JournalInternational Journal of Hematology
Volume76 Suppl 1
DOIs
StatePublished - Jan 1 2002

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?'. Together they form a unique fingerprint.

Cite this